Introduction
More than 500 000 infants are born prematurely each year, and many will have respiratory distress syndrome (RDS) at birth. 1 In spite of surfactant treatment of acute RDS in the first days of life, premature infants can have a secondary respiratory decompensation necessitating increased oxygen and ventilator pressures. The clinical sequelae of increased ventilatory support may continue for days or even weeks and carry significant risk for preterm infants struggling to develop respiratory competency.
In total, 30% of low birth weight infants will progress to chronic lung disease (CLD), characterized by arrested alveolar development and interstitial fibrosis. 2 Although the relationship of decompensation after the first week of life and the development of CLD is complex, there is evidence that this secondary respiratory decompensation involves damage to the surfactant system. In one study of 68 infants <30 weeks gestation, 75% of infants who remained intubated >7 days had dysfunctional surfactant. 3 Respiratory deterioration, measured by worsening respiratory severity score (RSS), was evident in those infants with surfactant deficiency.
Previous studies report that exogenous surfactant may be beneficial in selected infants with secondary respiratory decompensation from various etiologies. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] This pilot study was designed to evaluate the magnitude of short-term effects of secondary surfactant administration in a population of premature infants with respiratory decompensation after recovery from RDS. We hypothesized that most of these acutely ill preterm infants would have derangement of surfactant production or activity and that administration of surfactant in these older infants would be well tolerated and result in improving blood gases and ventilator settings.
Methods
In this prospective, nonrandomized, unblinded, pilot study, infants acted as their own controls with blood gas measurements and ventilatory parameters before and after two doses of surfactant 12 h apart, administered within 4 h of a respiratory decompensation. Two different surfactants, Survanta (Ross Products, Abbott Laboratories, Columbus, OH, USA) and Curosurf (Dey Inc., Napa Valley, CA, USA), were used to begin exploratory analyses of effects of different amounts of surfactant proteins and phospholipids. Patients were given the surfactants on an alternating basis (quasi-randomization), receiving either Survanta (S) or Curosurf (C). This study was approved by the Human Investigations Review Board at the Medical University of South Carolina (MUSC).
Eligibility and entry criteria
Infants were eligible for the study if they were X7 days but p3 months of life, with birth weights >500 g with an admitting diagnosis of RDS. Prospective informed consent was obtained from the parents to enable rapid administration of surfactant, within 4 h of a qualifying respiratory decompensation. Acute decompensation was determined by increased respiratory support that was noncardiac in origin, accompanied by bilateral, diffuse parenchymal lung disease on chest X-ray and defined by one of the following:
Infant on a nasal cannula, hood oxygen or nasal continuous positive airway pressure who required reintubation and mechanical ventilation due to respiratory deterioration. Infant on minimal ventilator settings who required increased ventilatory support defined as an increase in both mean airway pressure (MAP)X2 above the infant's baseline, and in absolute fraction of inspired oxygen (FiO 2 ) by 20% or more above baseline and sustained for 4 h. Infant who required change to high-frequency ventilation (HFV) due to failure of conventional ventilation during the respiratory decompensation.
Infants were excluded due to congenital heart disease or lethal congenital anomalies, untreated patent ductus arteriosus (PDA) by cardiac echo or clinical exam, untreated pulmonary air leak, untreated hematocrit less than 30% or participation in other therapeutic clinical trials.
Surfactant and study protocol
Infants received 4 cc kg À1 of Survanta or 2.5 cc kg À1 of Curosurf (1.25 cc kg À1 on second dose) per manufacturer's recommendations for the treatment of RDS. The standardized Neonatal Intensive Care Unit (NICU) protocol for administering surfactant was utilized throughout the study.
The first dose of surfactant was administered within 4 h of qualification. Patients qualified for the second dose if they remained intubated 12 h after the first dose with MAP >7 and FiO 2 >30%. Infants were manually bagged for surfactant administration, placed back on the ventilator immediately afterwards and ventilator settings were adjusted to meet the following blood gas goals: PCO 2 of 45 to 65, as required to keep the pH >7.25 after treating metabolic acidosis, and oxygen saturations of 92 to 96%, in accordance with NICU guidelines at the time in our institution. If excessive chest rise or tidal volumes >6 cc kg À1 were noted after surfactant administration, settings were adjusted immediately, as per standard NICU protocol.
Adverse events of desaturations, bradycardia, and endotracheal tube occlusion associated with each surfactant administration were recorded. The adverse events for desaturations or bradycardia were documented whenever oxygen saturations decreased 10 percentage points or heart rate dropped >20% below baseline, for >2 min despite manual ventilation with 100% oxygen. Grade III or IV intraventricular hemorrhage, significant bronchospasm requiring treatment with a bronchodilator, evidence of air leak, pulmonary interstitial emphysema, pulmonary hemorrhage and sustained changes in heart rate or blood pressure of >20% were recorded as serious adverse events if they occurred within 4 h of surfactant administration.
Outcome assessment
The primary outcome was a change in oxygenation and ventilation at 12 and 24 h following secondary surfactant therapy, measured by partial pressure of oxygen (PaO 2 ), partial pressure of carbon dioxide (PCO 2 ), pH, MAP, FiO 2 , intermittent mandatory ventilation rate (IMV) and DP. These measurements were documented prior to surfactant administration and at 12 and 24 h postadministration.
Secondary data analysis was performed with composite indices of respiratory severity (modified ventilatory index (MVI), RSS and ventilatory efficiency index (VEI)) to insure that changes in the PaO 2 , PCO 2 , pH and FiO 2 over time were related to improvement due to surfactant dosing and not changes in the ventilator settings. The RSS (FiO 2 Â MAP) is a modification of the oxygen index and is useful when PaO 2 values are not available. This score enables comparison of the severity of lung disease among patients when oxygen saturation goals are the same. 3, 16 RSS has recently been used to measure the severity of lung disease before and after surfactant therapy. 16 A reduction in RSS indicates improvement in indirect measures of oxygenation.
Ventilatory efficiency index allows for comparison of respiratory status under conditions where both ventilator pressures and PCO 2 values vary. 6, 18 VEI is defined as alveolar ventilation (ratio of CO 2 production to the mole fraction of alveolar PCO 2 )/ (PIPÀPEEP) Â ventilator rate. 18 VEI scores increase as pulmonary function improves.
Modified ventilatory indices is calculated by (PCO 2 Â PIP Â IMV rate)/1000. 19, 20 High MVI scores have been related to lung injury secondary to mechanical ventilation, and lower scores correlate with increased pulmonary compliance. In studies of congenital diaphragmatic hernia, MVI has been used to predict prognosis 21, 22 and may be better than PCO 2 alone. 23 Blood gases were sampled within 1 h before surfactant administration, and between 1 and 2 h after surfactant administration for each dose, then 12 h after the second dose. Whenever possible, arterial blood gases (ABGs) were obtained. If an indwelling arterial line was not available, arterial puncture was attempted twice before a venous or capillary blood gas (VBG/CBG) was obtained. X-rays were reviewed by pediatric radiologists blinded to the study, preadministration and 24 h postadministration.
Statistical analysis
To analyze changes over time, repeated-measures analysis of variance (ANOVA) was utilized. Paired t-tests were performed when the repeated-measures ANOVA was significant. The level of significance was set at Pp0.05. For the purposes of statistical Secondary surfactant deficiencyanalysis, patients were compared over three time periods: pre-surfactant; 12 h after dose 1 but before dose 2 and 12 h after dose 2 (corresponding to 24 h after first dose).
Both MVI and VEI include ventilator rate in their respective formulas, making inclusion of infants on HFV problematic. However, we used each infant as his/her own control, allowing the measurement of mean change over time by repeated-measures ANOVA.
Results were analyzed using SPSS (SPSS Inc., Chicago, IL, USA).
Results

Demographic data
Between January 2001 and November 2002, 409 infants were screened for enrollment, but 292 did not qualify due to early extubation to room air, transfer to level II nursery, expiration or meeting exclusion criteria before 7 days of age. The disposition of 37 infants was not recorded, as they were not available for consent at 7 days of age. A total of 80 parents were approached for consent, 29 refused, and 51 gave informed consent for the study. All consented infants had received Survanta for primary RDS. Nineteen of these infants had a qualifying respiratory decompensation related to blood stream infections or pneumonia and received secondary surfactant treatment. Nine infants received Survanta (S) and 10 infants received Curosurf (C). Sixteen of the infants entered into the study between 7 and 30 days of age. Three infants with CLD developed respiratory failure later in their hospital course and entered the study at 32, 45 and 77 days of age. Characteristics of the 19 infants are included in Table 1 . All (100%) of the mothers received prenatal care. Eleven (58%) had no maternal illness, four (21%) were diagnosed with chorioamnionitis, and four (21%) with hypertension. Preterm labor was present in 16 (84%) of the mothers. One patient was exposed to ruptured membranes <18 h; sixteen patients (84%) were exposed between 18 and 24 h. Maternal steroids were given to 18 (95%) of the mothers, with 1 not receiving steroids. Sixteen infants (84%) were inborn, with three (16%) being transported in from another hospital. Six infants (32%) were born by vaginal delivery and thirteen (68%) by cesarean section. At the time of respiratory decompensation all the infants were diagnosed with either pneumonia or confirmed sepsis. None of these infants had a diagnosed PDA upon entry into the study or within a week after the study. Also none of these infants required diuretics or steroids before, during or immediately after (within 3 days) the trial.
Secondary surfactant administration was associated with significant improvements in measures of oxygenation and ventilation A significant difference was found in PCO 2 (P<0.001), pH (P<0.001), MAP (P<0.05) and FiO 2 (P<0.05) over three time periods using repeated-measures ANOVA, but not for IMV or DP. Post hoc paired t-tests then identified a significant improvement for PCO 2 , pH, MAP and FiO 2 , when comparing values prior to dosing and to 12 and 24 h after secondary surfactant administration. Figures 1 and 2 show mean values for all 19 infants, indicating improvement in PCO 2 and pH following secondary surfactant administration. This improvement was maintained in all patients for at least 24 h after the first surfactant dose. No patients deteriorated during this time and none of the infants required bicarbonate treatment during the time of secondary administration.
Similar results were found with both MAP and FiO 2 over the same time period (Table 2 ). There was a significant decrease of 7% in MAP over time from pre-surfactant to 12 h post-surfactant. FiO 2 decreased 15% from pre-surfactant to post-surfactant administration. All improvements were sustained at the 24 h time period. Figure 3 ). Infants (75%) had a significant improvement in their RSS. MVI and VEI were first evaluated with all 19 patients. Mean differences in MVI scores were significant indicating improvement in ventilation and pulmonary compliance. Mean difference in VEI analyses showed a trend toward improvement, but this did not quite reach the level of significance (P ¼ 0.075). When looking at MVI and VEI by ventilator type, both MVI and VEI were significant when infants received secondary surfactant on high-frequency jet ventilation (HFJV). Repeated-measures ANOVAs for MVI in infants on both synchronized intermittent mandatory ventilation (SIMV) and HFJV prior to dosing compared to 12 and 24 h post-surfactant were significant (Table 3) . ANOVA for VEI was not significant in infants on SIMV although there was a trend toward significance (P<0.08).
Infants on HFJV had a significant improvement in VEI from pre-surfactant dosing compared to both 12 and 24 h post-surfactant dosing (P ¼ 0.03). There was no significant difference in MVI or VEI when comparing changes from 12 to 24 h indicating that the improvement was sustained during this time frame.
Surfactant composition may make a difference
In exploratory analyses Survanta and Curosurf groups were compared for changes in outcomes prior to surfactant dosing and at 1, 12 and 24 h after dosing. Although numbers are small, we found a significant decrease in PCO 2 (P<0.005) and a significant increase in pH (P ¼ 0.006), between the two groups 1 h after surfactant. No differences were found for FiO 2 , MAP, DP, IMV, VEI, MVI or RSS at 1 h, or for any outcomes at 12 or 24 h after dosing. All 19 infants had follow-up X-rays 24 h after surfactant administration. Among them, 53% of X-rays showed an overall improvement in aeration and diffuse lung disease after surfactant, 21% were unchanged and 26% had increased opacities.
Secondary surfactant administration was well tolerated by most patients There were six adverse events reported during the study dosing. Four infants (20%) had an episode of desaturation to 80% lasting approximately 2 min with the first dose, and two infants (10%) had desaturations of the same magnitude with the second dose. In one infant, the endotracheal tube became occluded with surfactant, which responded to an increase in peak inspiratory pressure (PIP) for 5 min. Serious adverse events included two infants with unstable saturations before dosing, who continued to have desaturations to 50 to 60% with dosing (1S, 1C). Two infants died, one from necrotizing enterocolitis (C) and one from overwhelming pseudomonas sepsis (S). These infants died 10 and 12 days after Secondary surfactant deficiencydosing. Other serious adverse events including IVH, bronchospasm or air leak were not observed.
Discussion
In this pilot trial of secondary surfactant administration in older neonates with acute respiratory deterioration, measures of oxygenation and ventilation significantly improved within 12 h after surfactant administration, and these improvements were sustained for 24 h. MAP and FiO 2 were able to be weaned, consistent with studies of surfactant effects in primary RDS. PCO 2 and pH improved significantly compared to pre-surfactant levels, without changes in IMV or DP, suggesting that the improvement may have been due to surfactant dosing. Blood gases can be misleading, when increased PCO 2 levels are due to inappropriate ventilator settings. Even in severe lung disease, higher MAPs might result in improvement in PaO 2 and FiO 2 . Composite indices, such as MVI, measure the intensity of respiratory support, taking into account variations in ventilator management by incorporating both therapies (IMV rate and PIP) and response to therapy (PCO 2 ). Both MVI and RSS are less provider dependent than some of the other parameters measured, and yet demonstrated significant improvements at 12 and 24 h. These measures give an added degree of confidence that the observed changes were due to surfactant administration and not to changes in ventilator settings. Although VEI improved, we were unable to show a significant difference with our sample size. The VEI is calculated using a ratio of CO 2 production to the mole fraction of alveolar PCO 2 and is based on a calculated constant rather than actual PCO 2 change. MVI may be a better indicator of lung injury and improvement.
Although the majority of infants showed a positive response to secondary surfactant, three infants did not demonstrate an improvement in their RSS. There were no differences in demographics between these infants and other study patients prior to study entry. Surfactant effects may depend on the type of pulmonary injury and the degree of surfactant dysfunction or inhibition. Atelectasis, capillary leak of fluid and protein, alveolar inflammation and the release of inflammatory mediators may play a role in inactivation of exogenous surfactant. Structural immaturity of the lung or other conditions unrelated to surfactant deficiency may be the predominant pathophysiology in some patients. Response to surfactant may also be influenced by the timing of treatment, the type of surfactant used, the way surfactant is administered, the volume of the dose or the number of doses. 24 The majority of surfactant studies in neonates have used bolus administration of four doses with the total volume of surfactant determined by patient body weight. 25 In older children with respiratory decompensation due to adult respiratory distress syndrome, effects of a single dose of surfactant persisted for 12 h, but there was no benefit seen with more than two doses. 26 Based on these results, we chose bolus administration of two doses of surfactant for the older neonates in this pilot study. However, clinical deterioration and the need for increased ventilatory support seen in some infants 12 h after administration may indicate the need for additional surfactant doses, and some infants who did not respond at all may have responded to larger doses.
In contrast to primary RDS, infants receiving secondary surfactant did not have improvement in ventilation and oxygenation in the first hour after surfactant administration. Significant improvement was first noted at 12 and 24 h, indicating a slower onset of action and more gradual decrease in surface tension. This delayed effect may be due to the differences in the baseline state of inflammation with sepsis and pneumonia, as well as higher alveolar content of surfactant inhibitory substances, such as fibrinogen and albumin, than in early primary RDS. Lungs that have been ventilated more than a week and under the acute stress of infection and inflammation would be expected to have greater activation of inflammatory cascades than lungs exposed to mechanical ventilation less than an hour. Secondary respiratory decompensation is, therefore, a different disease model than primary RDS, and surfactant's anti-inflammatory activity may be more crucial initially than the surface tension-reducing properties.
The study entry criteria required significant and sustained increases in ventilator settings for 4 h. We obtained consent prospectively after admission with a diagnosis of RDS, and were then able to administer surfactant shortly after qualifying criteria were met. It was our intent to allow enough time to ensure that Secondary surfactant deficiencyincreased ventilation requirements would be sustained, but not enough time for inflammation and the increased ventilatory settings to cause lung injury that was not amenable to surfactant treatment. The 4 to 6 h time window for intervention has support from a recent preterm animal model. In one study preterm lambs underwent intratracheal injection of recombinant interleukin (IL)-1a. 27 VEI showed a significant, progressive decrease from 2 to 6 h after onset of inflammation compared to control animals. Neutrophil recruitment to the lung and inflammatory cytokine (IL-1b, CXCL8 and IL-6) expression in lavage fluid paralleled the decline in pulmonary function after IL-1 administration. Interestingly, surfactant protein C mRNA levels were decreased by more than 50%, while surfactant protein B showed a nonsignificant trend to lower levels.
It can be difficult to know prospectively the exact cause of a respiratory deterioration and if it will be significant and not transient in nature. Sepsis and pneumonia, for example, are usually diagnosed retrospectively and sometimes not definitively, but more by clinical judgment. While this study design potentially allows for a heterogeneous group with different respiratory etiologies, our group was surprisingly homogeneous, with all patients having sepsis or pneumonia as presumptive causative events for their respiratory deterioration. Our study design was a pragmatic approach aimed at testing the entry criteria in their ability to identify a group of patients who might respond to surfactant therapy. If successful, these entry criteria would enhance the ability to generalize results in future clinical trials, since these are the clinical circumstances in which decisions regarding secondary surfactant administration will be made. From this pilot data, the majority of infants identified by these entry criteria seem to be able to respond to surfactant, if given early enough in the course of the secondary disease process.
We also had heterogeneity of sources of blood gases. We were, frankly, unable to obtain repeated arterial gases in many patients, as most of these older infants did not have arterial access at the time of decompensation. The majority of patients received an initial ABG followed by CBG or VBG, and therefore, we could not analyze differences in PaO 2 . For pH and PCO 2 values, the bias would be for PCO 2 levels to be higher and pH levels to be lower in the post-surfactant gas (VBG or CBG) compared to pre-surfactant gas (ABG). This bias would tend to underestimate the treatment effect, however, rather than overestimate it.
Secondary surfactant administration was well tolerated. The few adverse events related to dosing were limited to desaturations and bradycardia, which were easily managed by increasing peak pressure or FiO 2 during administration. Different surfactant products may have different effects on outcomes of pulmonary function, related to their composition. We had a small sample size, but infants in the Curosurf group seemed to have a significant improvement in both PCO 2 and pH immediately after administration, while the Survanta group did not. These exploratory results need confirmation in larger trials of secondary surfactant administration.
This study was a prospective, nonrandomized, pilot trial designed to provide proof of concept of efficacy of secondary surfactant administration on short-term outcomes of pulmonary function and evaluate safety of secondary surfactant administration. Our results have helped determined which outcome parameters are most sensitive to treatment, and expected adverse events associated with secondary surfactant administration. As surfactant was administered by an unblinded medical team, this uncontrolled pilot data may have introduced bias into the outcome measures, by differences in ventilator management in the study patients. Also the lack of a control group does not ensure that any changes observed would not have occurred over time without treatment. Future large clinical trials will need to include both blinding and control groups for definitive proof of efficacy.
Respiratory failure in premature infants is a complex pathophysiologic process with many different causes. Although there are limitations in current research, there is a small but growing body of evidence that surfactant treatment for respiratory decompensation is promising. Premature infants often have several episodes of respiratory decompensation during their hospital course that may impact long-term outcomes, such as length of stay and incidence of CLD. Although secondary surfactant administration may improve oxygenation and ventilation on a short-term basis, it is unknown whether these improvements will be sustained long term. Exogenous surfactant after the first week of life may expedite recovery, diminish morbidity and lower the cost of care for these infants at risk for CLD.
In summary, surfactant therapy has been proven effective in the management of infants with initial RDS, but little research has been done on secondary events that can lead to surfactant dysfunction or deficiency in these premature infants. There have been several small studies demonstrating that infants with sepsis or pneumonia who received secondary surfactant have improvement in gas exchange. 12, 16 This pilot study was designed to generate data regarding applicability of entry criteria, outcome measures that might respond to surfactant therapy and the magnitude of that effect. While these data are preliminary, they add to that growing body of evidence that secondary surfactant administration leads to short-term improvement in blood gas and ventilatory parameters, as well as indices of pulmonary function. Large, prospective, randomized-controlled studies are needed, evaluating both short-and long-term clinical outcomes, to establish the efficacy of administering surfactant to neonates who experience respiratory failure after recuperation from their initial RDS.
